Los Angeles Capital Management & Equity Research Inc. Invests $1.46 Million in Zimmer Biomet Holdings Inc (ZBH) Stock

Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 11,077 shares of the medical equipment provider’s stock, valued at approximately $1,456,000.

A number of other institutional investors also recently bought and sold shares of ZBH. Calamos Advisors LLC lifted its holdings in shares of Zimmer Biomet by 6.8% in the 3rd quarter. Calamos Advisors LLC now owns 36,675 shares of the medical equipment provider’s stock valued at $4,822,000 after buying an additional 2,322 shares during the period. Flinton Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 8.0% in the 2nd quarter. Flinton Capital Management LLC now owns 12,444 shares of the medical equipment provider’s stock valued at $1,387,000 after buying an additional 918 shares during the period. Schroder Investment Management Group lifted its holdings in shares of Zimmer Biomet by 71.5% in the 2nd quarter. Schroder Investment Management Group now owns 64,996 shares of the medical equipment provider’s stock valued at $7,233,000 after buying an additional 27,096 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Zimmer Biomet by 0.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 957,471 shares of the medical equipment provider’s stock valued at $106,700,000 after buying an additional 7,733 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Zimmer Biomet by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 983,726 shares of the medical equipment provider’s stock valued at $109,634,000 after buying an additional 21,825 shares during the period. 87.10% of the stock is owned by institutional investors.

Shares of ZBH stock opened at $112.40 on Wednesday. The firm has a market cap of $23.88 billion, a P/E ratio of 14.00, a PEG ratio of 2.37 and a beta of 1.16. Zimmer Biomet Holdings Inc has a 1 year low of $104.28 and a 1 year high of $134.55. The company has a quick ratio of 0.96, a current ratio of 1.89 and a debt-to-equity ratio of 0.70.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.03. The company had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. Zimmer Biomet’s revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.72 earnings per share. As a group, research analysts predict that Zimmer Biomet Holdings Inc will post 7.65 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend was Thursday, September 27th. Zimmer Biomet’s payout ratio is 11.96%.

Several analysts have recently commented on the company. Piper Jaffray Companies raised their price target on Zimmer Biomet from $110.00 to $120.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Oppenheimer reissued a “buy” rating and issued a $138.00 price target (up from $130.00) on shares of Zimmer Biomet in a report on Friday, July 27th. Raymond James raised their price target on Zimmer Biomet from $135.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, July 30th. Zacks Investment Research reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Saturday. Finally, JMP Securities lifted their price objective on Zimmer Biomet from $133.00 to $140.00 and gave the stock an “outperform” rating in a report on Monday, July 30th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $134.63.

In related news, CEO Bryan C. Hanson purchased 410 shares of the company’s stock in a transaction on Friday, August 31st. The stock was bought at an average price of $123.03 per share, with a total value of $50,442.30. Following the completion of the transaction, the chief executive officer now owns 25,487 shares of the company’s stock, valued at approximately $3,135,665.61. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Chad F. Phipps sold 30,100 shares of the firm’s stock in a transaction on Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The disclosure for this sale can be found here. Company insiders own 0.71% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Los Angeles Capital Management & Equity Research Inc. Invests $1.46 Million in Zimmer Biomet Holdings Inc (ZBH) Stock” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.themarketsdaily.com/2018/11/21/los-angeles-capital-management-equity-research-inc-invests-1-46-million-in-zimmer-biomet-holdings-inc-zbh-stock.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How is a Moving Average Calculated?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply